Low-dose gonadotropin releasing hormone agonist (Leuprorelin acetate) in the postoperative treatment of endometriosis-associated pain
- Author:
Banatao-Pua Jacqueline D.
;
Banal-Silao Maria Jesusa
- Publication Type:Journal Article
- MeSH:
Human;
GONADOTROPIN-RELEASING HORMONE;
ENDOMETRIOSIS
- From:
Philippine Journal of Reproductive Endocrinology and Infertility
2011;8(2):41-45
- CountryPhilippines
- Language:English
-
Abstract:
Background: Gonadotropin-releasing hormone agonist (GnHRa) is used postoperatively for pain eradication and recurrence prevention in patients with endometriosis. However, the hypoestrogenic state induced by these agents limits its acceptability and safety.
Objective: To know the effect of 1.88 mg monthly injection of GnHRa therapy for post-operative treatment of endometriosis-associated pain.
Methodology: Prospective longitudinal study conducted between May 2010-February 2011. Six patients with endometriosis-associated pain were given 1.88 mg GnHRa SC every 4 weeks for 12 weeks. Endometriosis-associated pain was graded using the Biberoglu and Behrman scale. Serum estradiol is measured and adverse symptoms were recorded.
Results: Mean pelvic pain scores during treatment were significantly lower than before treatment at all time points. Serum estradiol levels after the 2nd dose were within the therapeutic window (20-50 pg/ml) and remained so during the treatment period.
Conclusion: Half-dose GnHRa maintained therapeutic effectiveness is postoperative patients with enmetriosis-associated pain. Favorable levels of plasma estradiol were maintained wihtin therapeutic window. No adverse events were recorded.
